InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,631.22
(
0.28%
)
US TECH 100
19,892.00
(
0.50%
)
Dow Jones
40,211.72
(
0.53%
)
Brent Oil
84.14
(
-0.24%
)
Bitcoin
64,858.07
(
0.01%
)
Post# of 252606
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120052
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 49524

Wednesday, 08/22/2007 8:07:32 AM

Wednesday, August 22, 2007 8:07:32 AM

Post# of 252606
SemBioSys Updates Apo A1 Development Program

[Oops—commercial expression levels of Apo A1 Milano have been realized but (contrary to what was stated in the company’s 7/12/07 PR) commercial levels of native Apo A1 have not.]

http://biz.yahoo.com/prnews/070822/to265.html?.v=56

>>
Wednesday August 22, 7:00 am ET

- Canadian Biotechnology Company confirms commercial expression levels of Apo AI Milano variant and clarifies status of native Apo AI -

CALGARY, Aug. 22 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved commercial levels of apolipoprotein AI (native Apo AI) and apolipoprotein AI(Milano) (Apo AI Milano) accumulation in safflower seed lines. SemBioSys has confirmed in multiple assays that it has developed commercial levels of Apo AI Milano in safflower seed lines. Based on further evaluation of the existing data from native Apo AI safflower seed lines, the Company must clarify that, to date, it has not proven it has achieved commercial levels of native Apo AI accumulation in safflower.

While the assays demonstrate that native Apo AI accumulates in safflower, the commercial level threshold set by SemBioSys of 1% total seed protein expression has not yet been attained. Over the coming months SemBioSys will continue to analyze the additional safflower seed lines it currently has in development. The Company expects that the analysis of these seed lines will be complete by the end of the fourth quarter of 2007.

"While this is a setback to our native Apo AI program, we believe it is temporary in nature. Our success with the Milano variant has given us confidence that similar accumulation levels will be found among the remaining native Apo AI plant lines we have created. We successfully achieved the commercial threshold for Apo AI Milano early in our current series of seed lines. We initially believed we had achieved a similar outcome in an early seed line from the native Apo AI series. We are currently, and will continue, analyzing new seed lines between now and the end of 2007 as they become available," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "In the meantime, we will continue to scale-up the successful Apo AI Milano seed lines to allow us to initiate animal trials with this material as soon as possible."

SemBioSys expects to receive in vivo efficacy results from animal trials for Apo AI produced in its model plant system, Arabidopsis, before the end of 2007. The Company is currently scaling up safflower-produced Apo AI Milano in order to initiate preclinical animal trials as soon as sufficient material is available.

The Company currently intends to partner one, or both, of the native Apo AI and Apo AI Milano programs prior to or shortly after Phase I clinical trials in 2009. SemBioSys believes its proprietary oilbody-oleosin production system offers the potential to overcome the manufacturing cost and capacity challenges of traditional fermentation-based technologies that have impeded the commercial development of Apo AI.

About Apo AI

Apo AI is a developmental-stage cardiovascular therapy, designed to rapidly stabilize and diminish atherosclerotic plaque for the prevention and treatment of cardiovascular disease. Apo AI is the major apolipoprotein associated with HDL, commonly referred to as "good cholesterol", which naturally removes plaque from arteries. Apo AI Milano is a natural variant of native human Apo AI characterized by a single amino acid substitution in its primary structure. In an epidemiological study, Apo AI Milano appears to confer enhanced resistance to atherosclerosis, suggesting that it may offer clinical advantages in the treatment of cardiovascular disease.

In a six week clinical trial, Esperion Therapeutics (acquired by Pfizer in 2003) demonstrated that its Apo AI Milano variant/phospholipid formulation could reduce plaque volume at a level and speed of atherosclerotic regression unattainable with any current drug therapy. Similarly, both CSL Limited and Borean Pharma A/S have more recently confirmed the strong therapeutic potential of their respective Apo AI-based drug candidates (CSL-111 and Trimeric Apo A-I) in clinical and preclinical trials.

High dosing (up to 20 grams per course of patient treatment) coupled with a large patient population is expected to drive volume demand of several tonnes of Apo AI per year, underscoring the value of a highly scalable plant manufacturing solution.

About Cardiovascular Disease

Atherosclerotic cardiovascular diseases are the leading cause of mortality in developed nations and by 2010 are projected to become the leading cause of mortality worldwide. In the United States coronary heart disease and stroke account for 70% of cardiovascular-related deaths, which claims more lives each year than the next four leading causes of death combined (cancer, respiratory disease, accidents and diabetes). Drugs positioned in the cholesterol and triglyceride management market are the single largest class of prescription pharmaceuticals, with global sales exceeding US$35 billion in 2006.

About SemBioSys Genetics Inc. (www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up